The forecast data indicates a consistent growth trend in the import of blood-grouping reagents to China from 2024 to 2028, with values escalating from 72.205 million USD in 2024 to 82.342 million USD in 2028. The year-on-year variation from 2024 to 2028 shows a steady increase, reflecting a CAGR of approximately 3.3% over this period. The import value in 2023, not specified here, served as a baseline prior to this forecasted growth.

Future trends to watch include:

China's expanding healthcare infrastructure and increasing demand for diagnostic tools could further boost imports.
Regulatory changes and technological advancements in blood testing could influence import patterns.
Global supply chain factors and trade relations might impact the consistency of these imports.